SAR444245

Phase 2Small molecule

SAR444245 is one of 50 small molecule programs targeting Oropharynx Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oropharynx Squamous Cell CarcinomaActive, not recruiting

Duchenne Muscular DystrophyActive, not recruiting

Oropharynx Squamous Cell CarcinomaPhase 2

Active, not recruiting

Duchenne Muscular DystrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

125 competitors in Duchenne Muscular Dystrophy

#DrugCompanyPhaseTrials

Cialis

Eli Lilly

Phase 3

2 2

Aldactone

Pfizer

Phase 3

1 3

Rifadin

Sanofi

Phase 3

1 4

Nolvadex

AstraZeneca

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

6 6

Rayos

RRoxane Laboratories

Phase 3

5 7

Duvyzat

Italfarmaco

Phase 3

2 8

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 9

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 10

Creatine Monohydrate

MMassachusetts General Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oropharynx Squamous Cell Carcinoma1 trial

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05535023

Head and Neck1 trial

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

Terminated· Sanofi logo

Sanofi·Phase 2·NCT05061420·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SAR444245. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR444245 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR444245. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

SAR444245

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oropharynx Squamous Cell Carcinoma1 trial

Head and Neck1 trial

References

Drug Info

Quick Facts

Related News